Cover Image
市場調查報告書

Nintedanib(大腸癌症):市場預測與分析

Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 321692
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
Nintedanib(大腸癌症):市場預測與分析 Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年11月28日 內容資訊: 英文 70 Pages
簡介

Boehringer Ingelheim目前在美國、歐洲、日本針對難治性大腸癌治療,正在進行口服式抗VEGF抑制劑Nintedanib (BIBF-1120)的開發。實驗有764名患者參加,以安慰劑比較實驗·雙重盲檢法·隨機法等各種手法進行第Ⅲ期實驗。為了提升實驗的有效性,有資格參加實驗的患者僅限為轉移性,其他治療法(5-FU、xaliplatin、irinotecan、Avastin、Zaltrap、(如果是野生型KRAS的情況下)非EGFR療法)無效的患者。實驗目前在疾病無進展生存期(PFS)方面雖是一次實驗,但整體生存者(OS)、客觀反應率(ORR)、疾病管理方面則已是第二實驗結束階段。2016年下半期預定實驗數據即將完成。

本報告提供大腸癌症的治療藥之一──Nintedanib(BIBF-1120)的全球市場相關分析,提供大腸癌症概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Nintedanib的商品資訊(特色·功效·安全性等),調查著全球主要國家的市場販售額預測(今後10年份)等。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定出版的相關調查報告

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 臨床階段
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 篩檢及診斷
    • 治療的指南及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 未滿足需求及機會

  • 概要
  • 具有大幅改善轉移性患者存活率可能性的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 針對KRAS·BRAF突然變異陽性的患者之標靶治療
  • 是針對高風險且可切除之轉移部位,有效果的新佐劑/佐劑治療方法
  • 針對化療抗性患者之後期治療

第7章 開發平台評估

  • 概要
  • 臨床實驗階段的有潛力的藥劑

第8章 Nintedanib (BIBF-1120)

  • 概要
  • 有效性
  • 安全性
  • 給藥及製劑
  • 在臨床方面·商業方面的潛在的定位
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄
Product Code: GDHC479DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally available anti-VEGF inhibitor, for the treatment of refractory CRC in the US, Europe, and Japan. The drug is being investigated in a placebo-controlled, double-blind, randomized Phase III study in 764 metastatic CRC patients. To be eligible for the trial, patients must be refractory to multiple previous treatments for metastatic disease, including 5-FU, oxaliplatin, irinotecan, Avastin or Zaltrap, and anti-EGFR therapy if KRAS wild-type. Previous treatment with Stivarga is allowed. The trial has a primary endpoint of PFS, with secondary endpoints including OS, ORR, and disease control. The trial is due to report data for PFS in the second half of 2016.

Scope

  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Nintedanib including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Nintedanib for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Nintedanib performance
  • Obtain sales forecast for Nintedanib from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Nintedanib (BIBF-1120)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. SWOT Analysis
  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Colorectal Cancer Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Average Body Weight and Surface Area Across the 8MM
    • 9.4.5. Generic Erosion
    • 9.4.6. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Treatment Guidelines for CRC
  • Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
  • Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
  • Table 6: Leading Treatments for CRC, 2014
  • Table 7: Unmet Need and Opportunity in CRC
  • Table 8: Product Profile - Nintedanib
  • Table 9: Nintedanib SWOT Analysis, 2014
  • Table 10: Global Sales Forecasts ($m) for Nintedanib, 2013-2023
  • Table 11: Average Body Weight and Surface Area Across the 8MM
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: CRC - Phase III Pipeline
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023
  • Figure 3: Clinical and Commercial Positioning of Nintedanib
Back to Top